An ISO 31000-Based Risk Matrix for Risk Management in Anticancer Drug Prescription, Compounding, and Administration

Alessandro Morabito1, Piera Maiolino2, Stefania D'Auria3

  • 1Thoracic Department, Division of Thoracic Medical Oncology, Istituto Nazionale Tumori "Fondazione G. Pascale", IRCCS, Napoli, Italy.

Abstract

Insights

This study reduced risks in lung cancer Day Hospital care by applying ISO 31000 risk management. Implementing mitigation actions significantly lowered organizational risks and improved patient safety outcomes.

Area of Science:

  • Oncology
  • Healthcare Management
  • Patient Safety

Background:

  • Lung cancer patients undergoing anticancer drug therapy in Day Hospitals (DH) face potential patient safety and organizational risks.
  • Identifying and mitigating these risks is crucial for optimizing care delivery.

Purpose of the Study:

  • To identify and reduce risks impacting patient safety and organizational aspects during lung cancer therapy in a Day Hospital setting.
  • To implement and assess the effectiveness of risk mitigation strategies.

Main Methods:

  • A modified Delphi approach was used by a multidisciplinary team to identify care processes, activities, and risk factors.
  • A 5x5 semi-quantitative ISO 31000 risk matrix assessed harm severity and occurrence probability.
  • Improvement actions were identified and adopted to reduce risks.

Main Results:

  • 19 potential risks were identified, with 10 affecting patient safety and 9 impacting the organization.
  • Highest organizational risks included DH outpatient visits and drug administration.
  • Post-mitigation, high-level organizational risks decreased from 44.4% to 0.0%, and moderate patient safety risks reduced from 50.0% to 10.0%.

Conclusions:

  • The ISO 31000 risk management framework effectively improved both organizational and safety objectives in lung cancer Day Hospital care.
  • This systematic approach enhances the overall quality and safety of oncology patient management.

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
508
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
328
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
232
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
661
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
47
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
264